{"architecture":{"family":"Not disclosed. Checked on 2026-09-06: the manufacturer's site (screenpoint-medical.com) gives no network type, backbone, parameter count or training-data description; it documents clinical validation and regulatory clearances instead.","input":"Screening mammography \u2014 full-field digital mammography (2D) and digital breast tomosynthesis (3D), described by the manufacturer as vendor agnostic.","output":"Region markings and an examination-level score used as reader decision support (manufacturer's product description).","params":"not disclosed by the manufacturer"},"article":null,"cancer_slugs":["invasive-breast-carcinoma"],"category":"screening","confidence":"medium","datasets":[],"developer":"ScreenPoint Medical","evaluation":[{"benchmark":"MASAI randomised trial (Sweden), first results","external":true,"metric":"cancer detection rate / reader workload","source":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00298-X/abstract","value":"AI-supported screening: similar cancer detection with 44% lower screen-reading workload (Lancet Oncol 2023)"}],"hf":null,"kind":"product","license":"proprietary","limitations":"- Closed weights; performance depends on vendor and population.\n- Trial evidence is programme-specific (Swedish double-reading setting).","links":{"demo":null,"docs":"https://screenpoint-medical.com/","doi":null,"github":null,"huggingface":null,"paper":null,"pmid":null},"modalities":["mammography"],"name":"Transpara","notable_uses":"In the MASAI trial, AI-supported reading increased cancer detection while reducing screen-reading workload by 44% (safety analysis, The Lancet Oncology 2023). Final results (The Lancet, 2026) reported 12% fewer interval cancers and 27% fewer aggressive cancer subtypes, with false-positive rates similar to standard double reading.","openness":"closed","regulatory":{"details_en":"Manufacturer states (verified 2026-09-06): \"Transpara is CE marked and FDA cleared for 2D and 3D mammography. CE (0344) certified. FDA 510(k) K241831 and K232096.\" Cleared for full-field digital mammography (FFDM) and digital breast tomosynthesis (DBT); described by the manufacturer as vendor agnostic. Always check the clearance covering the specific software version deployed at your site.","details_pl":"Producent podaje (zweryfikowano 6.09.2026): Transpara ma znak CE (jednostka notyfikowana 0344) oraz dopuszczenie FDA 510(k) K241831 i K232096 dla mammografii 2D i 3D. Dopuszczenie obejmuje mammografi\u0119 cyfrow\u0105 (FFDM) i tomosyntez\u0119 (DBT); producent opisuje oprogramowanie jako niezalezne od producenta aparatu. Zakres dopuszczenia zawsze sprawdzaj dla konkretnej wdrozonej wersji oprogramowania.","intended_use_en":"Decision support in screening mammography.","intended_use_pl":"Wsparcie decyzji w mammografii przesiewowej.","source_url":"https://screenpoint-medical.com/","status":"fda-cleared"},"regulatory_status":"fda-cleared","release_date":null,"run_snippet":"","settings":["screening"],"slug":"transpara","sources":[{"label":"L\u00e5ng K et al. Artificial intelligence-supported screen reading versus standard double reading in the MASAI trial. Lancet Oncol 2023","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00298-X/abstract"},{"label":"ScreenPoint Medical \u2014 Transpara","url":"https://screenpoint-medical.com/"}],"summary":"Commercial mammography AI with FDA clearance and CE marking, used as a concurrent or replacement reader in breast screening; the MASAI randomised trial in Sweden used it to triage screening reads.","tasks":["screening","detection"],"training":{"summary_en":"Not disclosed by the manufacturer. Checked on 2026-09-06: the ScreenPoint Medical site (screenpoint-medical.com) names no training dataset, no number of mammograms or examinations, no source institutions and no architecture; it documents FDA clearance, CE marking and clinical validation (including a randomised controlled trial) instead. Published training-corpus details for this device are not available from the vendor.","summary_pl":"Nieujawnione przez producenta. Sprawdzone 6.09.2026: strona ScreenPoint Medical (screenpoint-medical.com) nie podaje ani nazwy zbioru treningowego, ani liczby mammogramow czy badan, ani osrodkow, z ktorych pochodzily dane, ani architektury; zamiast tego dokumentuje dopuszczenie FDA, znak CE i walidacje kliniczna (w tym badanie z randomizacja). Producent nie udostepnia opisu zbioru treningowego."},"updated_at":"2026-09-06T15:37:13.700389","url":"/ai-oncology/models/transpara","usage":{},"verified_at":"2026-09-06T02:56:17.920346","verified_by":"Occe3C","version":null,"what_it_does":"Transpara supports radiologists reading screening mammograms by highlighting suspicious findings and triaging examinations to single or double reading. It is the system evaluated in MASAI, the first randomized controlled trial of AI in mammography screening, conducted within the Swedish national programme with over 105,000 participants."}